Pharmafile Logo

News and Press Releases

Barinthus Bio Names Experienced Physician, Leon Hooftman MD, as Chief Medical Officer 

Dr Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, haematology, oncology and infectious diseases 1 May 2024 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical...

Category: BioManufacturing, Drug Discovery
Posted: May 1, 2024

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

Veklury (remdesivir) recommended by NICE for treatment of COVID-19 in vulnerable adults and children

Remdesivir is the first antiviral treatment recommended by NICE to treat eligible children, including those with a high risk of serious illness from COVID-19 This decision secures long-term access to...

Category: Pharmaceutical
Posted: April 9, 2024

Gilead Sciences, Inc

Viroclinics-DDL Changes Name to Cerba Research

14 March 2024 -- Rotterdam, the Netherlands -- Viroclinics-DDL (referred to herein as Cerba Research, the Netherlands), a world leading vaccine and antiviral specialty laboratory providing research and clinical trial...

Category: Biotechnology, Clinical Trials
Posted: March 15, 2024

Cerba Research
Klaartestraat 20, 9052 Ghent, Belgium

New partnership aims to advance vaccine against MERS coronavirus

CEPI to invest up to $47m to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500 VTP-500 project with Barinthus Bio and University of Oxford, UK, uses...

Category: Clinical Trials
Posted: January 2, 2024

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD 

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level...

Category: Drug Discovery
Posted: November 27, 2023

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T-Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity and Cancer

New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data  6 November 2023 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical company developing novel...

Category: Drug Discovery
Posted: November 27, 2023

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023

Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...

Category: Clinical Trials
Posted: October 12, 2023

AstraZeneca
Medical.InformationUK@astrazeneca.com
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...

Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

New exploratory analysis of phase 3 SCORPIO-SR study data in Asia suggests that ensitrelvir may reduce the risk of persistent and new late-onset symptoms associated with long COVID-19 over one...

Category: Clinical Trials
Posted: September 20, 2023

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

MODERNA RECEIVES US FDA APPROVAL FOR UPDATED COVID-19 VACCINE

Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86 Updated vaccine to be available in pharmacies and care settings across the US in the...

Category: Clinical Trials
Posted: September 12, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

NIH and Exothera collaborate to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US

16 August 2023 -- Maryland, US and Jumet, Belgium -- The National Institutes of Health (NIH), the US’s medical research agency, selected Exothera, a full-service Contract Development and Manufacturing Organisation...

Category: Other
Posted: August 23, 2023

Exothera
Zoning de Jumet, Allée Centrale 52, 6040 Jumet - BELGIUM

MODERNA CLINICAL TRIAL DATA CONFIRMS ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS 

Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variant  Updated vaccine expected to be available, pending approval, in coming weeks...

Category: Other
Posted: August 22, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139